MedTrace Logo

An Observation Study to Assess the Efficacy and Safety of Proportional Doses of Painkyl® in Patients With Breakthrough Cancer Pain

NCT05209906 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2022-08-23

No results posted yet for this study

Summary

An open-label, single arm, observation study, to assess the efficacy and safety of proportional doses of Painkyl® in patients with breakthrough cancer pain.

Conditions

  • Cancer Pain

Interventions

DRUG

Fentanyl Buccal Soluble Film

Eligible patients will receive Painkyl® for dose of 200, 400, 600, 800, 1000 or 1200 mcg for the treatment of breakthrough pain according to around-the-clock morphine daily dose.

Sponsors & Collaborators

  • Mackay Memorial Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-06
Primary Completion
2022-08-15
Completion
2022-08-15

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05209906 on ClinicalTrials.gov